Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, EMEACLA and JAPAC | July 07, 2024 | July 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date July 07, 2024 · Filed July 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 184,685.8054 |
Reported balance
After 2024-07-07 transaction · row 1
1 source rowRow 1 · 2024-07-07 · Tax withholding · Disposed 82 · Balance 184,685.8054 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2022 Filed May 11, 2022 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006814 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,514.3402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2022 Filed May 11, 2022 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 51 | $100.52 | $5,126.52 |
DisclosureSEC source: 0001225208-22-006814 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,983.3402 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 42 | $105.93 | $4,449.06 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,034.3402 Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,425 Underlying: Common Stock · 3,425 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 24,500 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,076.3402 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 23:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,660 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-22-005750 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,560 Underlying: Common Stock · 11,660 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 23:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,560 | $123.29 | $1,425,264.77 |
DisclosureSEC source: 0001225208-22-005750 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,326.3402 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $122.57 to $123.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 23:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 100 | $123.57 | $12,357.00 |
DisclosureSEC source: 0001225208-22-005750 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,886.3402 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 23:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,660 | $21.76 | $253,721.60 |
DisclosureSEC source: 0001225208-22-005750 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,986.3402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. Read SEC document |
| March 11, 2022 Filed Mar 12, 2022 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,660 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-22-004574 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,220 Underlying: Common Stock · 11,660 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2022 Filed Mar 12, 2022 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,535 | $105.65 | $690,409.68 |
DisclosureSEC source: 0001225208-22-004574 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103.487 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $105.14 to $106.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2022 Filed Mar 12, 2022 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,125 | $106.47 | $545,661.83 |
DisclosureSEC source: 0001225208-22-004574 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,638.487 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $106.18 to $106.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2022 Filed Mar 12, 2022 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,660 | $21.76 | $253,721.60 |
DisclosureSEC source: 0001225208-22-004574 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,763.487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 01:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 100 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-21-014184 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,880 Underlying: Common Stock · 100 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 01:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 100 | $110.58 | $11,058.00 |
DisclosureSEC source: 0001225208-21-014184 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103.487 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 01:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 100 | $21.76 | $2,176.00 |
DisclosureSEC source: 0001225208-21-014184 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,203.487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 10,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008307 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,631 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 623 | $89.49 | $55,752.27 |
DisclosureSEC source: 0001225208-21-008307 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,062.138 Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 143 | $89.49 | $12,797.07 |
DisclosureSEC source: 0001225208-21-008307 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,685.138 Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008307 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,828.138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 11, 2021 Filed May 13, 2021 01:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 143 | $90.40 | $12,927.20 |
DisclosureSEC source: 0001225208-21-008063 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,197.138 Read SEC document |
| May 07, 2021 Filed May 11, 2021 14:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 51 | $91.75 | $4,679.25 |
DisclosureSEC source: 0001225208-21-007900 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,340.138 Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007708 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,550 Underlying: Common Stock · 3,550 shares Expires 2028-05-03 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 27,800 | $0.00 Strike: $93.31 | $0.00 |
DisclosureSEC source: 0001225208-21-007708 · doc4.xml · derivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,800 Underlying: Common Stock · 27,800 shares Expires 2028-05-03 F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007708 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,391.138 F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,020 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-21-006242 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,020 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,020 | $83.66 | $1,089,263.62 |
DisclosureSEC source: 0001225208-21-006242 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,541.138 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.1600 to $84.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,020 | $13.98 | $182,019.60 |
DisclosureSEC source: 0001225208-21-006242 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,561.138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,020 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-21-004099 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,020 Underlying: Common Stock · 13,020 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,592 | $84.58 | $811,289.44 |
DisclosureSEC source: 0001225208-21-004099 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,220.7448 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.9900 to $84.9800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,428 | $85.11 | $291,773.53 |
DisclosureSEC source: 0001225208-21-004099 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,812.7448 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.9900 to $85.3050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,020 | $13.98 | $182,019.60 |
DisclosureSEC source: 0001225208-21-004099 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,240.7448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,020 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-21-001360 · doc4.xml · derivative · entry 5 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,040 Underlying: Common Stock · 13,020 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,503 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001225208-21-001360 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,503 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 20,523 | $83.51 | $1,713,787.48 |
DisclosureSEC source: 0001225208-21-001360 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,220.7448 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.1600 to $83.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,503 | $11.35 | $85,159.05 |
DisclosureSEC source: 0001225208-21-001360 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,743.7448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,020 | $13.98 | $182,019.60 |
DisclosureSEC source: 0001225208-21-001360 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,240.7448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,020 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-21-000102 · doc4.xml · derivative · entry 5 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,060 Underlying: Common Stock · 13,020 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,503 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001225208-21-000102 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,503 Underlying: Common Stock · 7,503 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 20,523 | $91.24 | $1,872,475.42 |
DisclosureSEC source: 0001225208-21-000102 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,220.7448 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.6600 to $91.6200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,503 | $11.35 | $85,159.05 |
DisclosureSEC source: 0001225208-21-000102 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,743.7448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,020 | $13.98 | $182,019.60 |
DisclosureSEC source: 0001225208-21-000102 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,240.7448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2020. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 25 | $225.05 | $5,626.25 |
DisclosureSEC source: 0001225208-20-007573 · doc4.xml · nonDerivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,385.0477 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 3,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007573 · doc4.xml · derivative · entry 5 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 210 | $217.84 | $45,746.40 |
DisclosureSEC source: 0001225208-20-007573 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,410.0477 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 48 | $217.84 | $10,456.32 |
DisclosureSEC source: 0001225208-20-007573 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,620.0477 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007573 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,668.0477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 1,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007342 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,425 Underlying: Common Stock · 1,425 shares Expires 2027-05-06 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 11,500 | $0.00 Strike: $218.04 | $0.00 |
DisclosureSEC source: 0001225208-20-007342 · doc4.xml · derivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2027-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.